Roche’s Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer

0
41

Roche’s Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer

LEAVE A REPLY

Please enter your comment!
Please enter your name here